In the heart, adenosine binds to pharmacologically distinct G-protein-coupled receptors (A 1 -R, A 2A -R, and A 3 -R). While the role of A 1and A 3 -Rs in the heart has been clarified, the effect of genetically manipulating the A 2A -R has not been defined. Thus, we created mice overexpressing a cardiac-restricted A 2A -R transgene. Mice with both low (Lo) and high (Hi) levels of A 2A -R overexpression demonstrated an increase in cardiac contractility at 12 weeks. These changes were associated with a significantly higher systolic but not diastolic [Ca 2+ ] i , higher maximal contraction amplitudes, and a significantly enhanced sarcoplasmic reticulum Ca 2+ uptake activity. At 20 weeks, the effects of A 2A -R overexpression on cardiac contractility diminished. The positive effects elicited by A 2A -R overexpression differ from the heart failure phenotype we observed with A 1 -R overexpresson. Interestingly, coexpression of A 2A -R TG Hi , but not A 2A -R TGLo, enhanced survival, prevented the development of left ventricular dysfunction and heart failure, and improved Ca 2+ handling in mice overexpressing the A 1 -R. These results suggest that adenosine-mediated signaling in the heart requires a balance between A 1 -and A 2A -Rs--a finding that may have important implications for the ongoing clinical evaluation of adenosine receptor subtype-specific agonists and antagonists for the treatment of cardiovascular diseases.
Introduction
The ubiquitous purine nucleotide, adenosine, regulates a variety of cardiac pathways. including growth and differentiation, angiogenesis, coronary blood flow, cardiac conduction, and heart rate, as well as mediating the cardioprotective process of ischemic preconditioning. These biologic actions of adenosine are mediated by a family of G-protein-coupled receptors found on the sarcolemmal surface of cardiac myocytes, including the A 1 -, A 2A -, and A 3 -adenosine receptors (R) and the A 2B -R, which is expressed only in the cardiac vasculature. 1 In contrast to other G-proteincoupled receptors in the heart, activation of select adenosine receptor subtypes can result in diametrically opposite physiologic effects. For example, activation of the A 1 -R or A 3 -R pathways inhibits adenylyl cyclase due to coupling with the inhibitory guanine nucleotide binding protein G i . 2 By contrast, activation of the A 2A -R enhances the production of the intracellular second messenger cAMP through G s -mediated activation of adenylyl cyclase. Thus, these two receptor-mediated signaling pathways subserve very different physiologic functions, leading investigators to propose that the role of A 2A -R in the normal heart is to reduce A 1 -R mediated antiadrenergic actions. 3 Studies using transgenic mouse models harboring a transgene overexpressing the A 1 -R or A 3 -R 4-6 as well as mice in which the A 1 -R has been ablated 7 have helped to clarify the role of these receptor subtypes and have confirmed their importance in cardiac protection during ischemia-reperfusion and myocardial infarction. 8 Interestingly, recent studies using transgenic models have suggested that robust activation of A 1 -R and A 3 -R can have adverse consequences on cardiac morphology and function, albeit in a strain-and dose-specific manner. [9] [10] [11] While transgenic models have helped to clarify the role of A 1 / A 3 -R pathways in cardiac physiology, the role of A 2A -R pathway in the heart has remained controversial. For example, studies have shown disparate effects of A 2A -R activation on cardiac contractility. [12] [13] [14] [15] This controversy is due in large part to the fact that subtype-selective adenosine receptor agonists and antagonists lack receptor-subtype selectivity and to species-specific responses to pharmacologic agents. 16 Therefore, to more effectively evaluate the role of A 2A -R in cardiac physiology, we created transgenic mice with cardiac-restricted overexpression of the A 2A -R. In contrast with mice overexpressing the A 1 -R, overexpression of the A 2A -R markedly enhanced cardiac function. These salutary effects of A 2A -R activation on myocardium were due at least in part to enhanced sarcoplasmic reticulum Ca 2+ uptake, resulting in higher systolic but not diastolic [Ca 2+ ] i . Furthermore, overexpression of the A 2A -R prevented the cardiodepressant effects of A 1 -R activation. These results provide important insights regarding the use of adenosine receptor subtype-selective agonists and antagonists in the treatment of patients with cardiovascular diseases.
Materials and Methods

Transgenic mouse generation
Experiments were carried out in transgenic mice with cardiacrestricted constitutive overexpression of the human A 2A -R engineered on an FVB background as previously described. 9, 17 All protocols were approved by the Institutional Animal Care and Use Committee of Thomas Jefferson University.
Methods: Calculating Copy Number of Inserted Transgene
To quantify the number of transgenes inserted into the genome, genomic DNA from mouse-tail was isolated using the Qiagen DNAeasy kit. 100 ng of genomic DNA were used for Real-time PCR using the A 2A -AR-specific primer set (5′-CAG CTG AAG
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Immunoblotting and histopathology of myocardium Frozen ventricular tissues were homogenized on ice using a nonionic detergent-based lysis buffer (25 mM Tris-HCl pH 7.6, 137 mM NaCl, 10% glycerol, 1% NP40, or IGEPAL CA-630, 10 mM NaF) freshly supplemented with 1 mM sodium pyrophosphate, 5 µg/mL leupeptin, 5 µg/mL aprotinin, 1 mM EDTA, 10 mM PMSF, and 1 mM NaVO4. After electrophoresis in SDS-PAGE and transfer onto nitrocellulose membranes, the blots were probed with anti-A 1 -R (Affinity BioReagents), anti-A 2A -R (Millipore), anti-actin (Sigma), anti-Gαi (Abcam), anti-NCX1 (Swant), anti-SERCA2 (Bethyl lab), anti-pT308-Akt (Cell Signaling), anti-total Akt (BD Biosciences), anti-calsequestrin (Swant) and anti-Na + -K + -ATPase (Gift from Dr. R. Levenson, Pennsylvania State University) as previously described. 9, 20 For anti-A 1 -R and anti-A 2A -R blots, special precaution was taken to denature protein extract in the absence of reducing agent at 70°C for 5 minutes. All blots were incubated with either IRDye 700 or 800 secondary antibodies and visualized using the Odyssey Infrared Imaging System software (Li-Cor, Lincoln, NE, USA). Histopathology staining was performed by RADIL, University of Missouri and imaged at TJU Pathology Imaging Facility.
Isolation of adult murine cardiac myocytes
Cardiac myocytes were isolated from the septum and left ventricular free wall of wild-type and transgenic mice (male, 8-9week old) as recently described. 20 Briefly, mice were heparinized (1,500 U/kg ip) and anesthetized (pentobarbital sodium, 50 mg/kg ip). Excised heart was mounted on a steel cannula and retrograde perfused (100 cmH 2 O, 37°C) with Ca 2+ -free bicarbonate buffer followed by enzymatic digestion (collagenases B and D, protease XIV). Isolated myocytes were cultured on laminin-coated glass cover slips and the Ca 2+ concentration of the buffer was progressively increased from 0.05 to 0.125 to 0.25 to 0.5 mM in three steps (10-minute interval each). The 0.5 mM Ca 2+ buffer was then aspirated and replaced with minimal essential medium (MEM, Sigma M1018) containing 1.2 mM Ca 2+ , 2.5% FBS, and antibiotics (1% penicillin/streptomycin). After 1 hour (5% CO 2 , 37°), media were replaced with FBS-free MEM. Myocytes were used within 2-8 hours of isolation.
Myocyte shortening measurements
Myocytes adherent to cover slips were bathed in 0.6 mL of air-and temperature-equilibrated (37°), HEPES-buffered (20 mM, pH 7.4) medium 199 containing 0.6, 1.8, or 5.0 mM [Ca 2+ ] o . Measurements of myocyte contraction (1 Hz) were performed using a chargecoupled device video camera and edge-detection software (Ionoptix, Milton, MA, USA) as previously described. [20] [21] [22] [Ca 2+ ] i transient measurements Myocytes were exposed to 0.67 µM of fura-2 AM for 15 minutes at 37°C. Fura-2-loaded myocytes were field-stimulated to contract (1 Hz, 37°C) in medium 199 containing 0.6, 1.8, or 5.0 mM [Ca 2+ ] o . Fura-2-loaded myocytes mounted on [Ca 2+ ] i transient measurements using a Dvorak-Stotler chamber situated in a temperature-controlled stage (37°C) of a Zeiss IM 35 inverted microscope were performed as previously described. [20] [21] [22] Immunofluorescence microscopy Freshly isolated myocytes were fixed in 2 mM EGTA/phosphatebuffers saline (PBS-EGTA) containing 4% paraformaldehyde, 20 minutes at room temperature. Cells were washed with PBS-EGTA and pelleted by centrifugation (Beckman GS6, 600 rpm, 5 minutes). Approximately 3,000 rod-shaped myocytes suspended in 600 µL PBS-EGTA were mounted onto polylysine-coated slides by cytospin (400 rpm, 2 minutes). The mounted myocytes were made permeable by incubating with blocking buffer (0.01 M Tris-HCl, pH7.5, 0.15 M NaCl, 0.1% BSA and 0.002% NaN3) containing 0.2% Triton X-100 for 5 minutes at room temperature. Subsequently, the slides were incubated with anti-A 1 -R (Affinity BioReagents), anti-A 2A -R (Millipore and Affinity BioReagents) and anti-α-actinin (Sigma) antibodies in a 37°C humidified incubator for 45 minutes. After rinsing with blocking buffer, the myocytes were incubated with Alexa-594-conjugated anti-rabbit and Alexa-488-conjugated anti-mouse secondary antibodies (1:2,000) and 350 nM DAPI nuclear stain. After incubation and washing, the myocyte slides were mounted and sealed with ProLong® Gold reagent (Invitrogen) and stored in the dark at 2-6°C. Myocyte images were taken with a Confocal Microscope (Zeiss LSM 510 META Confocal, KCC Bioimaging facility).
Statistics
All results are expressed as means ± SE. Kaplan-Meier survival curves were compared between groups using log-rank tests. Twoway analysis of variance was used to analyze the calcium transient and contraction results. Commercial software package were used for all statistical analysis (JMP version 4.05; SAS Institute, Cary, NC, USA) or SPSS for Windows (version 11.5). Categorical differences were analyzed using the Mann-Whitney test. In all analyses, p < 0.05 was taken to be statistically significant.
in part to a lack of balance in the endogenous stoichiometry of the A 1 -and A 2A -Rs. To test this hypothesis, we created double recombinants harboring both the A 1 -R and A 2A -R Hi transgenes (A 1 /A 2A -TG Hi ). As seen in Figure 3A , coexpression of the A 1 -R and A 2A -R transgenes did not influence the expression of either the A 1 -R or A 2A -R receptors when compared with mice in which either the A 1 -R-or A 2A -R transgenes were expressed alone. Also, immunofluorescence microscopy of isolated myocytes confirmed that both receptors colocalized to the sarcolemmal surface ( Figure 3B) . Importantly, while mice overexpressing A 1 -R alone developed profound cardiac dilatation, A 2A -R coexpression prevented the profound cardiac dilatation in A 1 -TG mice (Figure 3C) . Furthermore, as seen in Figure 4 , coexpression of the A 1 -R and A 2A -R transgenes significantly
Results
Creation of transgenic mice overexpress ing the A 2A -adenosine receptor
We placed the human A 2A -adenosine receptor (A 2A -R) cDNA under the control of a cardiac-specific promoter as described previously. 9 Using an anti-A 2A -R antibody, we analyzed levels of A 2A -R expression in both wild-type and 15 lines of transgenic mice. Based on these measurements, the transgenic lines were classified as low expression (2-5×, A 2A -TG Lo ) or high expression (more than 50×, A 2A -TG Hi ) (Figure 1A) . Transgenic expression was confirmed at the mRNA level by real-time polymerase chain reaction RT-PCR (Data not shown). Consistently, RT-PCR assay showed that the A 2A -TG Lo line has seven genomic copies of the transgene, whereas, the A 2A -TG Hi line has over 25 copies (Figure 2) . Immunofluorescence staining of permeabilized myocytes showed that the overexpressed A 2A -R receptors were mostly localized at the sarcolemma (Figure 1B) .
A2A-R overexpression increased cardiac contractility
As seen in Table 1 , overex pression of the A 2A -R resulted in a small but significant increase in left ventricular mass (ventricular wt/ body wt) at 8-12 weeks in mice with high levels of A 2A -R overexpression but not in those with low levels of A 2A -R overexpression. Interestingly, heart rates and wall thickness were significantly increased when compared with WT mice, but they were not significantly different between A 2A -TG Hi and A 2A -TG Lo transgenic lines ( Table 1) . Furthermore, measurements of single cell morphology showed no increase in either ve nt r i c u l ar myo c y t e width or length ( Figure  1C) . Echocardiography demonstrated an increase in heart rate and fractional shortening as well as a significant decrease in left ventricular end-systolic dimension (LVESD) in mice with both high and low levels of A 2A -R overexpression ( Table 1) .
Overexpression of the A2A-R prevents the development of the cardiomyopathic phenotype in mice overexpressing the A1-R
In a previous study, we demonstrated that constitutive overexpression of the A 1 -R decreased cardiac contractility in FVB mice. 9 The present finding that A 2A -R increased cardiac contractility led us to hypothesize that the adverse effects of A 1 -R overexpression were due at least improved cardiac hemodynamics when compared with mice overexpressing the A 1 -R. Indeed, fractional shortening, left ventricular end-diastolic pressures, +dp/dt, and −dp/dt were similar in A 1 /A 2A -TG mice and wild-type controls. However, heart rate remained depressed in the A 1 /A 2A -TG mice, albeit at a rate significantly higher than that seen in the A 1 -TG mice.
Furthermore, as seen in Figure 5A , coexpression of the A 1 -R and A 2A -R Hi transgenes significantly improved survival compared to mice overexpressing A 1 -R alone. By contrast, coexpression of the A 1 -R with the transgenic line expressing lower levels of A 2A -R (A 2A -R TG Lo ) had no effect on the cardiac phenotype when compared with A 1 -TG mice (Figure 5B and data not shown).
Overexpression of A2A-R enhances myocyte [Ca 2+ ]i transport
In view of the marked increase in contractility in the A 2A -TG Hi mice and their ability to prevent heart failure in the A 1 -TG mice, we hypothesized that mice harboring the A 2A transgene might have enhanced Ca 2+ handling. To test this hypothesis, we first compared Ca 2+ handling in myocytes isolated from A 2A -TG Hi, A 1 -TG, and wild-type nontransgenic littermates. As seen in Figure  5C and Table 2 , when compared to WT myocytes, constitutive overexpression of A 2A -R resulted in significant higher systolic (p < 0.0001) but not diastolic [Ca 2+ ] i (p < 0.60). Maximal contraction amplitudes (p < 0.0001), maximal shortening (p < 0.0003), and relengthening velocities (p < 0.006) were all higher in myoctyes overexpressing A 2A -R ( Table 2) . Sarcoplasmic reticulum (SR) Ca 2+ uptake activity was significantly faster (p < 0.0001). By contrast, myocytes in which A 1 -R was constitutively overexpressed had significantly lower systolic (p < 0.0005) and Table 2) . Altered [Ca 2+ ] i transients in myocytes with constitutively overexpressed A 1 -R resulted in decreased maximal contraction amplitudes as well as maximal shortening and relengthening velocities (p < 0.0001 for all three parameters; Table  2 ). Furthermore, the t 1 / 2 of [Ca 2+ ] i transient decline, an estimate of sarcoplasmic reticulum Ca 2+ uptake, 23 was significantly prolonged in A 1 -R TG myocytes when compared with WT (p < 0.0001) myocytes.
Co-overexpression of A1-and A2A-R ameliorates the abnormal [Ca 2+ ]i handling seen in the A1-R TG myocytes
When analyzing myocyte function in our dual A 1 -/ A 2A -R mice, we found that the overexpression of the A 2A -R significantly ameliorated the contractile abnormalities observed in A 1 -R TG myocytes (p < 0.0001 for maximal contraction amplitude, maximal shortening, and relengthening velocities, Table 2 ). In addition, maximal contraction amplitude of A 1 / A 2A -R TG myocytes was significantly higher (p < 0.015) than that observed in WT myocytes but lower (p < 0.05) than that measured in A 2A -R overexpressed myocytes ( Table 2) . With respect to [Ca 2+ ] i homeostasis, SR Ca 2+ uptake activity (p < 0.0001) and systolic (p < 0.0001) but not diastolic [Ca 2+ ] i (p < 0.36) was improved by co-overexpression of A 1 and A 2A -R when compared with constitutive overexpression of A 1 -R alone ( Table 2 ). Diastolic [Ca 2+ ] i was significantly lower in A 1 /A 2A myocytes when compared to WT (p < 0.0001) or A 2A-R overexpressed (p < 0.0001) myocytes. The t 1 / 2 of [Ca 2+ ] i transient decline was significantly shorter in A 1 /A 2A myocytes when compared to WT myocytes (p < 0.009) but longer when compared to A 2A -R overexpressed myocytes (p < 0.002).
Effects of enhanced A 2A -R signaling on biochemical pathways in the heart
In order to understand the mechanisms responsible for the enhanced contractility effected by increased A 2A -R signaling, we assessed the levels of proteins involved in Ca 2+ homeostasis and G-protein-coupled receptor signaling in the heart. As seen in Figure 5D , the amount of SERCA2 was significantly increased in hearts from A 2A -R TG Hi mice when compared with wild-type controls. The level of SERCA2 protein was also significantly elevated in A 1 /A 2A -TG Hi mice but by contrast was significantly lower than WT controls in mice overexpressing the A 1 -R. The levels of the Na+ pump and NCX1 in the A 2A -TG mice had changing trends, but they were not statistically different from the WT mice. By contrast, mice overexpressing the A 1 -R had decreased Na + pump protein levels. It is interesting to note that co-overexpression of A 2A -R in A 1 -TG mice enhanced the expression of all three proteins involved in Ca 2+ homeostasis when compared to mice expressing only A 1 -R (Figure 5D and Table 2 ). However, the change in contractility seen in the A 2A -R TG Hi mice as well as in the A 2A -R TG Lo mice was not associated with an increase in steady-state adenylyl cyclase activity (data not shown). By contrast, levels of the G-inhibitory 
For calcium transient and contraction measurements, numbers in parentheses are myocytes pooled from 4-5 mice/genotype group. Mouse groups: wild-type (WT), A2A-TGHi, A1-TG) and A1/A2A-TG. Values are means ± SE. Two-way analysis of variance was used for analysis. * p< 0.05, compared to WT; $ p < 0.0001, A1-TG vs. A1-TG/A2A-TGHi; + p< 0.05, A2A-TG vs. A1-TG/A2A-TGHi. Protein expression was determined by immunoblotting. Numbers in parentheses are number of hearts from each mouse group. Signal band intensities on each blot were normalized to the average intensity of that protein measured in wild-type hearts. One-way analysis of variance followed by Dunnett's test was used to analyze the results. * p< 0.05, compared to WT; $ A1-TG vs, A2A-TGHi or A1-TG vs. A1/A2A-TGHi. protein, Gi-2, as well as the levels of mRNA encoding Gi-2 were increased in all three experimental models (A 2A -TG Hi , A 1 -TG, A 1 /A 2A -TG; Figure 5D and data not shown).
Long-term effects of enhanced A 2A -R signaling
Although overexpression of the A 2A -R markedly enhanced cardiac contractility in mice up to 12 weeks of age, long-term overexpression was not associated with an increase in cardiac contractility. Indeed, cardiac function was identical in 20week-old transgenic and nontransgenic controls as seen by measurement of fractional shortening (42 ± 2.0% WT, n = 7 vs. 40.3 ± 3.4% A 2A -TG Hi , n = 13, p = NS). At 20 weeks, A 2A -TG mice remained hypertrophied, but without dilation (data not shown). However, compared to younger mice, the 20-week-old A 2A -TG hearts developed significant fibrosis (Figure 6) . Furthermore, the fibrosis progressively worsened at 30 weeks (data not shown). Also, SERCA2 levels were not elevated in 20-week-old A 2A -TG Hi mice (1.1 ± 0.1, n = 7) when compared with wild-type controls (1.0 ± 0.1, n = 13, p = NS). Similarly, while phosphorylation (i.e., activation) of Akt was significantly enhanced in young mice (12 weeks old) overexpressing the A 2A -R transgene (1.03 ± 0.2 WT, n = 3 vs. 1.8 ± 0.16, A 2A -TG Hi , n = 6, p < 0.01), pAkt levels were not elevated in 20-week-old A 2A -R TG Hi mice (0.91 ± 0.12, n = 9) when compared with wild-type controls (1.12 ± 0.15, n = 7, p = NS). However, levels of Gi remained elevated in the hearts of the 20-week-old A 2A -TG Hi mice (1.9 ± 0.3 A 2A -R TG Hi , n = 13 vs. 1.0 ± 0.1 WT, n = 7, p < 0.01).
Discussion
In the present study, we have utilized cardiac-restricted overexpression of the A 2A -R to assess for the first time the effects of A 2A -R-signaling on cardiac morphology and function independent of the limitations imposed by experiments utilizing receptor subtype "selective" agonists and antagonists. Constitutive overexpression of the A 2A -R in young mice resulted in super normal contractility, which was associated with a modest increase in heart rate and a small but significant increase in LV mass. In myocytes isolated from hearts overexpressing the A 2A -R, systolic but not diastolic [Ca 2+ ] i was elevated and t 1 / 2 of [Ca 2+ ] i transient decline was much shorter when compared with wildtype controls and myocyte size did not change. These observations are consistent with enhanced SR Ca 2+ uptake, resulting in increased SR Ca 2+ content, more Ca 2+ available for release per beat, and larger systolic [Ca 2+ ] i values and twitch amplitudes in A 2A -R overexpressed myocytes. In support of this mechanism of action is the observation that SERCA2 but not Na + -K + -ATPase or NCX1 expression was increased in A 2A -R overexpressed myocytes. Thus, viewed in terms of excitation-contraction coupling, the major alteration induced by A 2A -R overexpression was increased SERCA2 expression and SR Ca 2+ uptake activity.
These findings are disparate from previous studies evaluating the role of adenosine receptor subtype-specific agonists and antagonists, which suggested that A 2A -R-mediated inotropy was accompanied by only a small increase in Ca 2+ transients leading investigators to suggest that the A 2A -R-induced contractile effects were mediated by Ca 2+ -independent inotropic mechanisms. 24 Furthermore, these earlier studies also suggested that A 2A -R activation could increase shortening and the rate of maximal shortening in isolated myocytes without an effect on maximal rate of relaxation 25 while in isolated hearts, A 2A -R activation could increase left ventricular pressure and the maximal rate of pressure development (+dP/dt/ max) without influencing cardiac relaxation. 14 By contrast, in this study we demonstrate enhanced contractility as well as enhanced relaxation, these effects being associated with increased expression of SERCA2 and robust changes in Ca 2+ handling. Importantly, the changes in cardiac function after A 2A -R overexpression were not due to an increase in heart rate as we were able to see enhanced contractility both in vivo as well as in isolated and paced myocytes. The disparity between the present results and earlier studies may be due to the lack of "specificity" of pharmacologic agonists and antagonists. However, we cannot exclude the possibility of speciesrelated differences as earlier studies were performed in rats.
Because of the contrasting effects of A 1 -and A 2A -R overexpression on cardiac function, we wondered whether abnormalities in calcium homeostasis might also be responsible for the adverse effects of A 1 -R overexpression. Indeed, left ventricular myocyte contractility was severely depressed in A 1 -TG myocytes. In addition, systolic [Ca 2+ ] i in A 1 -R myocytes was lower at all 3 [Ca 2+ ] o examined, suggesting that SR Ca 2+ uptake was diminished. 26 The decreased SERCA2 expression and prolonged t 1 / 2 of [Ca 2+ ] i transient decline in A 1 -TG myocytes are consistent with defective SR Ca 2+ uptake activity, resulting in decreased SR Ca 2+ content and diminished twitch amplitudes. Diastolic [Ca 2+ ] i was also lower with A 1 -R overexpression, suggesting that accelerated Ca 2+ efflux may further contribute to reduced SR Ca 2+ content and twitch amplitude. As one of the major alterations in excitation-contraction coupling in A 2A -TG myocytes was enhanced SERCA2 expression and SR Ca 2+ uptake, we hypothesized that enhanced A 2A -R signaling might ameliorate the negative inotropic effects of enhanced A 1 -R signaling. Indeed, co-overexpression of the A 2A -R improved cardiac contractility, decreased end-diastolic pressure, enhanced SERCA2 expression, and markedly improved survival when compared with mice overexpressing the A 1 -R. These salutary benefits were also seen at the single cell level as coexpression of the A 1 -R and A 2A -R ameliorated the marked cellular abnormalities found in the A 1 -TG mice. Because systolic [Ca 2+ ] i and t 1 / 2 of [Ca 2+ ] i transient decline improved without a change in diastolic [Ca 2+ ] i in the A 1 -/A 2A -TG mice when compared with A 1 -TG mice, it is likely that defects in SR Ca 2+ uptake but not Ca 2+ efflux pathways induced by constitutive A 1 -R overexpression were influenced by co-overexpression of A 2A -R. However, it is also noteworthy that the ability of A 2A -R signaling to ameliorate the adverse effects of A 1 -R overexpression was dose related as crossing the A 1 -TG with A 2A -R TG L o mice had no effect on cardiac hemodynamics or outcomes despite an increase in contractility in the A 2A -TG Lo mice.
Despite the salutary benefits of short-term overexpression of the A 2A -R, long-term benefits were not obvious as by 20 weeks of age, contractility decreases substantially to levels less similar to those seen in WT controls. Interestingly, this finding was consistent with results seen after overexpression of other G-protein-coupled receptors. For example, overexpression of the b 2 -adrenergic receptor (AR) results in left ventricular dysfunction in older mice while mice overexpressing the b 1 -AR develop significant LV dysfunction and early death. The markedly different phenotype in young mice overexpressing the b 2 -AR and those overexpressing the b 1 -AR has been attributed to the cardioprotective effects of enhanced Gi signaling in the b 2 -AR overexpressing mice. 27 The increase in Gi we observed in mice overexpressing the A 2A -R may have provided similar beneficial effects in young mice by limiting or opposing the effects of activation of Gs. However, it is interesting to note that in contrast with b-AR overexpression, both mice overexpressing the A 2A -R and mice overexpressing Gs 28 did not demonstrate an increase in steadystate adenylyl cyclase activity. Thus, the enhanced inotropy secondary to increased A 2A -R signaling in the mouse may be mediated through adenylyl cyclase dependent and independent pathways. Regardless, increased cardiac fibrosis in older A 2A -R overexpressing mice suggested a potential mechanism for diminishing contractile benefits derived from A 2A -R overexpression. Since A 2A -R, through G s coupling, increased cAMP-dependent transsarcolemmal calcium flux and contraction, it is highly possible that sustained contractile overdrive in A 2A -TG mice may ultimately lead to "calcium-overload" leading to dysfunction and structural injury. However, similar to the β-adrenergic receptor transgenic mice, 27 other pathways may also participate in the late myopathy.
Another possible explanation for the finding that early activation of A 2A -R signaling did not cause left ventricular dysfunction or pathology is the significant increase in Akt levels in young mice. Phosphorylation (activation) of Akt is known to have cardioprotective effects. 29 Indeed, while phosphorylation of Akt was enhanced in young mice overexpressing the A 2A -R, it was not increased in older A 2A -TG mice with "normalization" of left ventricular function. These results were consistent with our recent finding that Akt activity was substantially decreased in mice with left ventricular dysfunction secondary to overexpression of the A 1 -R. 9 Finally, our results suggest that the therapeutic usefulness of A 2A -R overexpression might be predicated on "dose" as despite an inability to reverse left ventricular dysfunction caused by A 1 -R overexpression, low levels of A 2A -R overexpression significantly increased cardiac contractility without causing an increase in either ventricular or atrial hypertrophy. Nonetheless, additional studies will be required to identify the role of low levels of A 2A -R overexpression in preventing or rescuing left ventricular dysfunction in other experimental models. Furthermore, additional studies using controlled overexpression of the A 2A -R receptor may shed additional light on the important downstream signaling pathways that play a role in the development of the early and late A 2A -R phenotype.
Taken together, our results suggest that despite the fact that the A 1 -R and A 2A -R signaling pathways affect different downstream events, the physiologic integrity of the heart, at least in a chronic sense, requires an ongoing balance between the activation of these two pathways. Indeed, the family of adenosine receptor subtypes is an anomaly because it is the only group of G-protein-coupled, seven-transmembrane-spanning receptors in which a single ligand can bind to multiple receptor subtypes in the same tissue and in so doing mediate opposing signaling pathways-that is, adenylyl cyclase activation in the case of the A 2A -R and adenylyl cyclase inhibition via the A 1 -R. Thus, it would appear axiomatic that the chronic use of subtype selective adenosine receptor agonists or antagonists might have unexpected consequences. These findings should be considered when designing adenosine agonists and/or antagonists for chronic use in patients with cardiovascular diseases.
Since the first description of the effect of adenosine on the heart by Drury and Szent-Györgyi in 1929, adenosine has inspired much research interest. 1 The original adenosine hypothesis proposed by Berne in 1963 stipulated that the release of adenosine by the myocardium reflects the metabolic state of the heart and regulates the vasomotor tone, coupling coronary blood flow to the energetic needs of the heart. 2 Since then, ample evidence has been shown that implicates endogenous adenosine as a mediator of cardioprotection in the setting of ischemia and reperfusion. Indeed, adenosine has been shown to limit infarct size and myocardial stunning in various models.
In all cell types, adenosine is continuously formed by dephosphorylation of AMP as a last step in the enzymatic cascade that catalyzes the breakdown of adenine nucleotides. Levels of adenosine are low under normal conditions. However, in the presence of ischemia, adenosine levels can rapidly increase up to 100-fold. Adenosine can be formed intra-and extracellularly and there is evidence that both sources of adenosine are important. Extracellular adenosine is derived from nucleotides, which have been shown to be released during inflammation and which are degraded by ecto-nucleotide triphosphate diphosphohydrolase (CD39) and ecto-5´-nucleotidase (CD73). Adenosine can be either rephosphorylated into AMP by adenosine kinase or degraded into inosine by adenosine deaminase. Most effects of adenosine are mediated through four different adenosine receptors: A1, A2a, A2b, and A3. 3 The A1 and A3 receptors preferably interact with Gi/o proteins and the A2a and A2b receptors with members of the Gs family of G proteins.
Experiments using adenosine agonists and antagonists have been limited by the absence of strong specificity and important differences among species. Therefore, genetically modified mice have been helpful to provide insights into the physiology of the different adenosine receptors. The following table is an attempt to summarize the results obtained with transgenic animals ( Table 1) . Of note, the majority of studies with transgenic mice have investigated the phenomenon of infarction and reperfusion, as it had been the case with pharmacological studies using adenosine receptor agonists and antagonists. Clinical trials with adenosine given at the time of reperfusion (AMISTAD I and II) have shown mixed results and have demonstrated a reduction in infarct size only when adenosine is administered early after infarction. 14, 15 The exact role of adenosine and its different receptors in the failing myocardium remains to be elucidated. It is known that plasma adenosine levels are elevated in patients with heart failure. 16 In the kidney, the A1 receptor plays an important role in the regulation of renal blood flow and diuresis and A1 antagonists have been used with success in heart failure patients in small clinical trials. 17 Besides coronary blood flow, adenosine regulates angiogenesis, heart rate, substrate metabolism, sensitivity to adrenergic stimulation, levels of proinflammatory cytokines, and levels of matrix metalloproteinases, which are all critically important in heart failure. In addition, patients with heart failure who present a nonsense mutation in the AMP deaminase gene, resulting in high levels of adenosine, have a better outcome compared with patients without the mutation. 18 Using various transgenic mice models, Feldman's group has recently started to dissect the type of adenosine receptor involved in protecting the failing heart. The first observation came from mice with left ventricular dysfunction secondary to overexpression of tumor necrosis factor- or mice with aortic banding, which all demonstrated significant decreases in myocardial adenosine levels. 19 This came as a surprise and it remains unclear whether the marked decrease in myocardial adenosine is cardioprotective or maladaptive. The decrease in myocardial adenosine was seen both early and late in the development of cardiac dilatation and was associated with a large increase in A1 receptor levels and a small decrease in A2a receptor levels. This is in contrast with experiments performed on explanted hearts from patients with end-stage heart failure undergoing transplantation, where 
